461 related articles for article (PubMed ID: 231951)
1. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
2. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
3. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
4. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
Hutt V; Klör HU; Wechsler JG; Ditschuneit H
J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
[TBL] [Abstract][Full Text] [Related]
5. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
Artery; 1982; 10(4):266-85. PubMed ID: 7181672
[TBL] [Abstract][Full Text] [Related]
6. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins.
Hara T; Miller JP; Gotto AM; Patsch JR
Artery; 1981; 9(5):328-41. PubMed ID: 7316782
[TBL] [Abstract][Full Text] [Related]
7. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
9. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
10. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
Herrmann W; Reuter W
Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
[No Abstract] [Full Text] [Related]
11. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
[No Abstract] [Full Text] [Related]
12. Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population.
Jones GJ; Hewitt D; Godin GJ; Breckenridge WC; Bird J; Mishkel MA; Steiner G; Little JA
Can Med Assoc J; 1980 Jan; 122(1):37-8, 40-6. PubMed ID: 7363194
[TBL] [Abstract][Full Text] [Related]
13. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774
[TBL] [Abstract][Full Text] [Related]
14. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
[TBL] [Abstract][Full Text] [Related]
15. [Quantitative analysis of lipoproteins in hyperlipoproteinemias of type IIa, IIb and IV (author's transl)].
Loeper J; Goy-Loeper J; Rouffy J
Clin Chim Acta; 1979 Oct; 98(1-2):19-26. PubMed ID: 227624
[TBL] [Abstract][Full Text] [Related]
16. [Lipid composition of circulating lipoproteins in various types of hyperlipoproteinemia (author's transl)].
Jaillard J; Sezille G; Dewailly P; Fruchart JC
Diabete Metab; 1977 Sep; 3(3):159-64. PubMed ID: 199484
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
[TBL] [Abstract][Full Text] [Related]
19. Serum lipoprotein pattern after SAMe-treatment.
Rini GB; Di Fede G; Rotolo G; Rizzo G; Mascellino MR; Affronti M; Delle Vedove G
Boll Soc Ital Biol Sper; 1987 Oct; 63(10):919-22. PubMed ID: 3447603
[No Abstract] [Full Text] [Related]
20. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
